The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.

Trial Details

NCT ID
NCT05618041
Phase
NA
Sponsor
Hebei Senlang Biotechnology Inc., Ltd.
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • CAR-T Autologous T cell injection
Locations (sample)
  • Taiyuan, Shanxi, China|37.86944,112.56028

Key Eligibility Criteria

  • Sign the informed consent and be willing and able to comply with the visit, treatment protocol, laboratory examination, and other requirements of t…
  • Diagnosed as recurrent or refractory lymphoma, leukemia or myeloma;
  • Tumor cells express targets for CAR-T cell therapy (results: flow cytometry or Immunohistochemical test confirmation);
  • Age 14-75 (including threshold), gender unlimited;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →